Rabies Virus Glycoprotein with a Consensus Amino Acid Sequence and a Lysosome Targeting Signal Causes Effective Production of Antibodies in DNA-Immunized Mice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Safe and effective anti-rabies vaccines are intensely sought worldwide. DNA vaccines have already shown their efficacy and safety and have occupied a special place in the field. Two prototype anti-rabies DNA vaccines were compared for the potential to induce virus-specific antibody production. One vector contained a codon-optimized gene with a territory-adapted consensus sequence of the rabies virus glycoprotein. The other one expressed the same glycoprotein in fusion with a c-CD63 lysosome targeting motif at the C terminus. ELISA of serum samples from immunized mice showed that the c-CD63 variant induced more efficient antibody production and shifted the IgG2a/IgG1 ratio towards the Th2-type immune response. The results gave grounds to believe that the approach successfully applied to the rabies glycoprotein may help to develop new-generation anti-rabies vaccines.

About the authors

E. S. Starodubova

Engelhardt Institute of Molecular Biology

Author for correspondence.
Email: estarodubova@yandex.ru
Russian Federation, Moscow, 119991

Y. V. Kuzmenko

Engelhardt Institute of Molecular Biology

Email: estarodubova@yandex.ru
Russian Federation, Moscow, 119991

E. O. Pankova

Engelhardt Institute of Molecular Biology

Email: estarodubova@yandex.ru
Russian Federation, Moscow, 119991

A. A. Latanova

Engelhardt Institute of Molecular Biology

Email: estarodubova@yandex.ru
Russian Federation, Moscow, 119991

O. V. Preobrazhenskaya

Engelhardt Institute of Molecular Biology

Email: estarodubova@yandex.ru
Russian Federation, Moscow, 119991

V. L. Karpov

Engelhardt Institute of Molecular Biology

Email: estarodubova@yandex.ru
Russian Federation, Moscow, 119991

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Pleiades Publishing, Inc.